Cognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer’s Candidate, CT1812

Posted by & filed under News.

PITTSBURGH, October 16, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug CT1812 for the treatment of patients… Read more »

Cognition Therapeutics CEO Kenneth I. Moch to Present at Ladenburg Thalmann 2017 Healthcare Conference

Posted by & filed under News.

PITTSBURGH, September 20, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced that President & CEO Kenneth I. Moch will present at the Ladenburg Thalmann 2017 Healthcare Conference at 9:00 a.m. on September 26, 2017 at the… Read more »

Cognition Therapeutics CEO Kenneth I. Moch Hosting One-on-Ones at Mizuho Securities CNS Deep Management Day

Posted by & filed under News.

PITTSBURGH, September 7, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced that President & CEO Kenneth I. Moch will participate in the Mizuho Biotechnology Conference: CNS Deep Management Day on September 19, 2017 at the… Read more »

Function of Cognition Therapeutics’ Neurological Drug Screening Platform Presented at American Chemical Society National Meeting

Posted by & filed under News.

PITTSBURGH, Aug. 23, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that an oral presentation had been made at the American Chemical Society National Meeting highlighting the company’s phenotypic neuronal assay that has been… Read more »

Cognition Therapeutics Elects Lazard Vice Chairman Stephen Sands to Board of Directors

Posted by & filed under News.

Pittsburgh, Aug. 02, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that Stephen Sands has joined the Company’s Board of Directors. Mr. Sands, the Vice Chairman of Investment Banking and Chairman of the Global… Read more »

Cognition Therapeutics CEO Kenneth I. Moch to Present at Canaccord Genuity Annual Growth Conference

Posted by & filed under News.

PITTSBURGH, July 31, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced that President & CEO Kenneth I. Moch will present a corporate and clinical update at the Canaccord Genuity Annual Growth Conference on August 10,… Read more »

Cognition Therapeutics Reports Drug-Drug Interaction Results for CT1812, a Disease-Modifying Alzheimer’s Disease Candidate

Posted by & filed under News.

PITTSBURGH, July 19, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative small molecule therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today presented results of an open-label Phase 1 study of Cognition’s lead clinical candidate, CT1812. In this study, which was presented at the… Read more »

Cognition Therapeutics CEO Kenneth I. Moch Presenting at BioCentury Future Leaders Conference

Posted by & filed under News.

PITTSBURGH, April 3, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced that the company has been selected to present at the annual Future Leaders in the Biotech Industry conference hosted by BioCentury. Kenneth I. Moch,… Read more »

Cognition Therapeutics initiates US clinical testing of CT1812, a novel small molecule for the potential treatment of Alzheimer’s disease

Posted by & filed under News.

PITTSBURGH, Dec. 13, 2016 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced the initiation of U.S. clinical testing of CT1812, its proprietary first-in-class, orally available small molecule therapeutic being developed for the treatment of Alzheimer’s… Read more »

Cognition Therapeutics to Highlight CT1812 Safety Data at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

Posted by & filed under News.

PITTSBURGH, Dec. 5, 2016 /PRNewswire/ — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that its poster focused on CT1812 safety data, its proprietary first-in-class, orally available small molecule in development for the treatment of Alzheimer’s disease,… Read more »